In addressing the challenge of targeted PDT for atherosclerosis, Zou et al. developed chlorin e6 (Ce6)-loaded, CD68-modified liposomes, leveraging the macrophage-targeting ability of CD68 antibodies to enhance therapeutic efficacy [118]. This evidence concerns the gene CD68 and atherosclerosis.